Dr. John B. Korman, M.D.
Dermatology (Dermatology Physician)
Who else practices at this address →
Greenville County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- Medical University of South Carolina College of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 1,250
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: Medical University of South Carolina College of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
SC license 36633 -
Internal Medicine Physician
MA license L-243930
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Upstate Dermatology PA (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,250
- Services billed
- 7,290
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 3,838 | 645 |
| Established patient office or other outpatient visit, 20-29 minutes | 1,561 | 1,106 |
| Destruction of precancer skin growth, 1 growth | 989 | 777 |
| Biopsy of related skin growth, first growth | 292 | 256 |
| Destruction of precancer skin growth, 15 or more growths | 186 | 136 |
| New patient office or other outpatient visit, 30-44 minutes | 122 | 122 |
| Biopsy of related skin growth, each additional growth | 81 | 61 |
| Established patient office or other outpatient visit, 10-19 minutes | 77 | 67 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 28 | 25 |
| Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | 22 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Mupirocin Other prescribers in Greer, SC | 245 |
| Triamcinolone Acetonide Other prescribers in Greer, SC | 170 |
| Ketoconazole Other prescribers in Greer, SC | 121 |
| Hydrocortisone Other prescribers in Greer, SC | 104 |
| Clobetasol Propionate Other prescribers in Greer, SC | 103 |
| Doxycycline Hyclate Other prescribers in Greer, SC | 79 |
| Betamethasone Dipropionate Other prescribers in Greer, SC | 74 |
| Metronidazole Other prescribers in Greer, SC | 73 |
| Betamethasone Diprop Augmented (betamethasone/propylene glyc) | 72 |
| Clindamycin Phosphate Other prescribers in Greer, SC | 33 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 101 payments worth $1,780 in total to this clinician.
| Galderma Laboratories, L.P. | $220 |
|---|---|
| AbbVie Inc. | $218 |
| Genzyme Corporation | $189 |
| Janssen Biotech, Inc. | $167 |
| E.r. Squibb & Sons, L.l.c. | $150 |
| Incyte Corporation | $149 |
| Regeneron Healthcare Solutions, Inc. | $122 |
| Leo Pharma Inc. | $76.78 |
| Food and Beverage | $1,684 |
|---|---|
| Education | $96.12 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Jul 1, 2025 | Education Sotyktu · Immunology · in-kind | $82.95 |
| Janssen Pharmaceuticals, Inc Dec 16, 2025 | Education TREMFYA · Immunology · in-kind | $13.17 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $160,343 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Sanofi US Services Inc. · Completed · NCT06130566 - A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Sanofi US Services Inc. · Active, not recruiting · NCT06407934 - Phase 1 pkpd study 6 to 12 a study to determine the safety and tolerability of JAK1 in patients aged 6 to 12
Pfizer Inc. - Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Sun Pharmaceutical Industries Inc. - A phase 3 multicenter longterm open label study evaluating the safety and efficacy of abrocitinib with or without topical medications administered to pediatric participants aged 2 years and older with moderatetosevere…
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.